EAM Investors LLC Acquires New Holdings in bluebird bio, Inc. (BLUE)
EAM Investors LLC acquired a new position in bluebird bio, Inc. (NASDAQ:BLUE) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,311 shares of the biotechnology company’s stock, valued at approximately $2,515,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. QS Investors LLC grew its holdings in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Bank of Montreal Can grew its holdings in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the period. Turner Investments LLC purchased a new stake in bluebird bio in the second quarter worth about $184,000. Biondo Investment Advisors LLC purchased a new stake in bluebird bio in the third quarter worth about $203,000. Finally, SG Americas Securities LLC grew its holdings in bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares during the period.
In other bluebird bio news, insider Jeffrey T. Walsh sold 1,250 shares of the stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $107.06, for a total value of $133,825.00. Following the transaction, the insider now directly owns 28,555 shares in the company, valued at $3,057,098.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nick Leschly sold 25,667 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the completion of the transaction, the insider now owns 339,368 shares in the company, valued at $39,088,406.24. The disclosure for this sale can be found here. Insiders sold 193,168 shares of company stock worth $25,558,003 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.
A number of brokerages have weighed in on BLUE. Sanford C. Bernstein began coverage on shares of bluebird bio in a report on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective on the stock. BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. BMO Capital Markets restated a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a report on Friday, August 4th. Evercore ISI began coverage on shares of bluebird bio in a report on Wednesday, August 16th. They issued an “in-line” rating and a $102.00 price objective on the stock. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $158.00 price objective (up previously from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. bluebird bio presently has an average rating of “Buy” and an average target price of $131.05.
Shares of bluebird bio, Inc. (BLUE) traded up $0.20 during mid-day trading on Wednesday, reaching $167.45. 107,790 shares of the company traded hands, compared to its average volume of 837,667. bluebird bio, Inc. has a 52 week low of $56.80 and a 52 week high of $169.60.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same quarter in the prior year, the business posted ($2.07) EPS. The company’s revenue for the quarter was up 397.4% compared to the same quarter last year. analysts expect that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.